drugset / Trial / NCT06589713
Effect of Renal Impairment on Enpatoran Pharmacokinetics
Phase 1
Completed
34 enrolled
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the effect of renal impairment on the pharmacokinetics of enpatoran.
Timeline
- Start
- 2024-09-24
- Primary completion
- 2026-04-13
- Completion
- 2026-04-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Enpatoran | Small molecule | — | Oral |